SCHEMBL5402396

SCHEMBL5402396

COCC#Cc1cccc(Cn2nc3c(c2-c2cccc(C(=O)OC)c2)c(=O)n(C)c(=O)n3CC(C)C)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK10 P53779 1/20 0.37
ABHD6 Q9BV23 1/20 0.37
PDE1A P54750 1/20 0.36
PDE1B Q01064 1/20 0.36
PDE1C Q14123 1/20 0.36
TSHR P16473 2/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
GAA P10253 3/20 0.35
KDM4E B2RXH2 1/20 0.35
F2 P00734 1/20 0.35
F7 P08709 1/20 0.35
F3 P13726 1/20 0.35
LMNA P02545 2/20 0.34
MAPK8 P45983 1/20 0.34
ALDH1A1 P00352 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
PDE4A P27815 1/20 0.34
PDE4B Q07343 1/20 0.34
PDE4C Q08493 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5402683 0.92 MAPK10 (0.38) MAPK10ABHD6PDE1APDE1BPDE1C
SCHEMBL5400198 0.89 LMNA (0.37) MAPK10ABHD6PDE1APDE1BPDE1C
SCHEMBL5404642 0.87 PDE1A (0.37) PDE1APDE1BPDE1CMEN1KMT2A
SCHEMBL5400132 0.86 MAPK8 (0.44) MAPK10ABHD6PDE1APDE1BPDE1C
SCHEMBL5403125 0.86 MAPK10 (0.41) MAPK10ABHD6PDE1APDE1BPDE1C
SCHEMBL5405841 0.82 PDE1A (0.36) PDE1APDE1BPDE1C
SCHEMBL5411108 0.79 SLC16A1 (0.45) MAPK10TSHRMEN1KMT2AGAA
SCHEMBL5403200 0.79 PDE1B (0.39) PDE1APDE1BPDE1CMEN1KMT2A
SCHEMBL5411300 0.77 PDE1A (0.41) PDE1APDE1BPDE1CTSHRMEN1
SCHEMBL5397651 0.77 PDE1A (0.39) PDE1APDE1BPDE1CMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7285558-B2 Pyrazolo[3,4-d]pyrimidines inhibiting H. pylori infections ASTRAZENECA AB (SE) 2007-10-23 US disclosed
US-20040254183-A1 Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections ASTRAZENECA AB (SE) 2004-12-16 US disclosed
EP-1412355-A1 NEW PYRAZOLO(3,4-D)PYRIMIDINES INHIBITING H. PYLORI INFECTIONS AstraZeneca AB (SE) 2004-04-28 EP disclosed
WO-2003002567-A1 NEW PYRAZOLO[3,4-D]PYRIMIDINES INHIBITING H. PYLORI INFECTIONS ASTRAZENECA AB (SE) 2003-01-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254183-A1 Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections DPYD, HPGDS, PGC MAPK10 1074/4885ABHD6 4623/4885PDE1A 4056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.